A detailed history of Bank Of America Corp transactions in Caribou Biosciences, Inc. stock. As of the latest transaction made, Bank Of America Corp holds 4,162,347 shares of CRBU stock, worth $8.16 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
4,162,347
Previous 1,116,769 272.71%
Holding current value
$8.16 Million
Previous $5.74 Million 18.92%
% of portfolio
0.0%
Previous 0.0%

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

BUY
$1.62 - $5.05 $4.93 Million - $15.4 Million
3,045,578 Added 272.71%
4,162,347 $6.83 Million
Q1 2024

May 15, 2024

SELL
$4.82 - $8.26 $2.3 Million - $3.93 Million
-476,367 Reduced 29.9%
1,116,769 $5.74 Million
Q4 2023

Feb 14, 2024

SELL
$3.58 - $6.25 $4.15 Million - $7.24 Million
-1,158,354 Reduced 42.1%
1,593,136 $9.13 Million
Q2 2023

Aug 14, 2023

BUY
$4.04 - $5.47 $481,184 - $651,504
119,105 Added 4.52%
2,751,490 $11.7 Million
Q1 2023

May 12, 2023

BUY
$4.3 - $7.78 $3.39 Million - $6.13 Million
788,483 Added 42.76%
2,632,385 $14 Million
Q4 2022

Feb 10, 2023

BUY
$5.57 - $11.01 $9.29 Million - $18.4 Million
1,668,395 Added 950.61%
1,843,902 $11.6 Million
Q3 2022

Nov 14, 2022

BUY
$5.34 - $12.79 $546,607 - $1.31 Million
102,361 Added 139.94%
175,507 $1.85 Million
Q2 2022

Aug 12, 2022

BUY
$5.1 - $9.74 $273,207 - $521,771
53,570 Added 273.65%
73,146 $397,000
Q1 2022

May 16, 2022

SELL
$8.42 - $15.32 $594,165 - $1.08 Million
-70,566 Reduced 78.28%
19,576 $180,000
Q4 2021

Feb 08, 2022

BUY
$14.59 - $23.26 $813,640 - $1.3 Million
55,767 Added 162.23%
90,142 $1.36 Million
Q3 2021

Nov 15, 2021

BUY
$15.75 - $30.29 $541,406 - $1.04 Million
34,375 New
34,375 $821,000

Others Institutions Holding CRBU

About Caribou Biosciences, Inc.


  • Ticker CRBU
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 60,840,800
  • Market Cap $119M
  • Description
  • Caribou Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies and solid tumors in the United States and internationally. Its lead product candidates are CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1...
More about CRBU
Track This Portfolio

Track Bank Of America Corp Portfolio

Follow Bank Of America Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Bank Of America Corp , based on Form 13F filings with the SEC.

News

Stay updated on Bank Of America Corp with notifications on news.